Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

Ipsen – 2019 First Quarter results – April 24, 2019

Ipsen completes acquisition of Clementia Pharmaceuticals

Ipsen is present at ESGE Days with an educational symposium and two oral presentations

Building the market access ecosystem